- Medicine - Jul 20 First UK trial seeks to reduce challenging behaviour in pre- schoolers with learning disabilities
- Medicine - Jul 20 Honorary Degrees for high fliers
- Medicine - Jul 20 One in three cases of dementia could be prevented by targeting risk factors from childhood onwards
- Medicine - Jul 20 Low- cost drugs package saves lives of people starting HIV treatment late
- Medicine - Jul 19 New wiki site to unmask dealings of tobacco industry in Sri Lanka
- Life Sciences - Jul 19 UOFG TO LEAD A NEW £5M SCOTTISH MACROMOLECULAR IMAGING CENTRE
- Medicine - Jul 19 King's research informs major All- Party Parliamentary Inquiry into Arts, Health and Wellbeing
- Medicine - Jul 19 Silk "micrococoons" could be used in biotechnology and medicine
- Medicine - Jul 19 Podcast: Everest, drugs, and science on show
- Medicine - Jul 19 Sussex honours Debenhams designer who "came from absolutely nowhere"
- Medicine - Jul 18 Cancer survivor sets her sights on graduation
Liverpool spin-out gets further funding boost for bedside sepsis test
A University of Liverpool spin-out company, Sepsis Limited has secured further funding support to test a point of care diagnostic tool for the early detection of sepsis.
The Small Business Research Initiative for Healthcare ( SBRI Healthcare ), led by the Academic Health Science Networks ( AHSNs ), has awarded the company £100,000 for the first phase of testing a working prototype of a hand held device that will be used at the patient bedside for rapid diagnosis and treatment of sepsis.
The award is part of an NHS England initiative aimed at helping healthcare organisations to improve their flow of patients.
Often referred to as blood poisoning, sepsis is the major cause of death worldwide. In the UK, approximately 100,000 people are admitted to hospital with sepsis and around 37,000 people will die as a result of the condition.
Sepsis Limited, which was spun out in 2010, is founded on the ground breaking research of blood specialist Professor Cheng-Hock Toh from the University’s Institute of Infection and Global Health.
The company’s hand-held device can detect abnormal blood chemistry due to bacterial sepsis within minutes of sampling and before standard physiological sepsis is diagnosed. It has been designed to frequently monitor progression of symptoms with a view to improve and measure the appropriate use of antibiotics and collectively meet objectives of the Department of Health’s UK Five Year Antimicrobial Resistance Strategy 2013-2018 .
Professor Toh, who also provides direct patient care at the Royal Liverpool University Hospital, said: ‘This new funding is an important step in helping us to translate our research into a bedside test that can quickly diagnose life-threatening sepsis, improve antibiotic usage, and ultimately save lives.’
Last job offers
- Medicine/Pharmacology - 17.7
Nuffield Professorship of Clinical Medicine
- Medicine/Pharmacology - 17.7
Professor of Epidemiology
- Medicine/Pharmacology - 12.7
PA to Professor of Nursing - 57414
- Medicine/Pharmacology - 11.7
Professor and Director, Comprehensive Clinical Trials Unit at UCL
- Medicine/Pharmacology - 10.7
Programme Leaders (Professors)
- Medicine/Pharmacology - 7.7
Chair of Neuro-Oncology
- Medicine/Pharmacology - 4.7
Lecturer (Assistant Professor)/Senior Lecturer (Associate Professor) in Drug Discovery
- Medicine/Pharmacology - 22.6
Programme Lead - Reader / Professor in Structural Biology of Prion Diseases